Long-Term Efficacy and Safety of Twice-Yearly Inclisiran in Patients with ASCVD and Elevated LDL-C: A Post-Hoc Analysis of ORION-3, a 4-year Open-Label Extension Study

ORION-3 (NCT03060577) was a long-term (4-year) open-label extension to the Phase 2, double-blind, 360-day, placebo-controlled ORION-1 study. ORION-3 assessed the long-term efficacy and safety of twice-yearly inclisiran in 382 patients with atherosclerotic cardiovascular disease (ASCVD) or risk-equivalents and elevated low-density lipoprotein cholesterol (LDL-C), despite maximally tolerated statin therapy or other oral lipid-lowering therapy (LLT). Results from a post-hoc, exploratory, subgroup analysis in patients with established ASCVD are presented here.

Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Scott R. Wright, Kausik K Ray, Roland PT Troquay, Frank LJ Visseren, Ulf Landmesser, Wolfgang Koenig, Frederick J Raal, Lawrence A Leiter, Kelly Kleeman, Jackie Han, Gregory G. Schwartz Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research